Silence Therapeutics (SLN)
NASDAQ: SLN
· Real-Time Price · USD
6.06
0.22 (3.77%)
At close: Jun 02, 2025, 11:20 AM
Silence Therapeutics Revenue Breakdown
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Research Collaboration Income Revenue | 43.1M | 24.8M | 16.9M | 12.02M |
| Research Collaboration Income Revenue Growth | +73.79% | +46.75% | +40.56% | n/a |
| Royalty Income Revenue | 100K | 600K | 600K | 392K |
| Royalty Income Revenue Growth | -83.33% | 0.00% | +53.06% | n/a |
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
|---|---|---|---|---|
| Germany Revenue | 144K | 569K | 578K | 392K |
| Germany Revenue Growth | -74.69% | -1.56% | +47.45% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 7.68M | 5.4M | 5.6M | 5.29M | 5.17M | 4.12M | 4.96M | 5.12M | 6.45M | 3.47M | 5.83M | 4.55M | 5.77M | 5.41M | 5.47M | 5.38M | 3.75M | 2.49M | 2.67M | 2.58M | 2.58M | 2.49M | 2.49M | 2.33M | 2.33M | 3.07M | 3.07M | 2.34M | 2.34M | 1.72M | 1.72M | 1.51M | 1.51M | 959K | 959K | 1.02M | 1.02M | 646.5K | 646.5K | 681K | 681K |
| Selling, General, and Administrative Revenue Growth | +42.43% | -3.66% | +5.90% | +2.28% | +25.64% | -16.97% | -3.11% | -20.70% | +85.99% | -40.48% | +28.12% | -21.12% | +6.56% | -1.11% | +1.77% | +43.42% | +50.32% | -6.45% | +3.33% | 0.00% | +3.45% | 0.00% | +7.18% | 0.00% | -24.29% | 0.00% | +31.32% | 0.00% | +35.96% | 0.00% | +13.97% | 0.00% | +57.51% | 0.00% | -6.30% | 0.00% | +58.31% | 0.00% | -5.07% | 0.00% | n/a |
| Research and Development Revenue | 20.81M | 20.4M | 15.3M | 10.99M | 9.18M | 9.94M | 8.93M | 12.62M | 12.54M | 8.4M | 8.77M | 10.83M | 7.6M | 7.22M | 7.92M | 8.17M | 7.46M | 6.71M | 3.47M | 5.09M | 5.09M | 4.14M | 4.14M | 2.53M | 2.53M | 2.27M | 2.27M | 2.61M | 2.61M | 2.06M | 2.06M | 1.91M | 1.91M | 2.02M | 2.02M | 2.33M | 2.33M | 1.94M | 1.94M | 1.62M | 1.62M |
| Research and Development Revenue Growth | +2.00% | +33.32% | +39.20% | +19.78% | -7.63% | +11.23% | -29.18% | +0.61% | +49.29% | -4.24% | -19.03% | +42.47% | +5.25% | -8.74% | -3.07% | +9.51% | +11.13% | +93.51% | -31.86% | 0.00% | +22.91% | 0.00% | +63.87% | 0.00% | +11.54% | 0.00% | -13.07% | 0.00% | +26.32% | 0.00% | +8.10% | 0.00% | -5.54% | 0.00% | -13.47% | 0.00% | +20.45% | 0.00% | +19.77% | 0.00% | n/a |